Abstract 3554
Background
The phase 3 SPARTAN study evaluated the efficacy and safety of APA vs placebo (PBO) in men with high-risk nmCRPC. Because dose reductions/interruptions for the management of AEs that occur during treatment can affect drug efficacy, this analysis sought to understand the relationship of APA pharmacokinetic exposure and the primary end point of SPARTAN, MFS.
Methods
1207 pts were randomized in a 2:1 ratio to APA 240 mg/d or PBO. APA levels, and that of its active metabolite N-desmethyl APA (NAPA), were measured by a validated LC/MS/MS assay. APA and NAPA exposures were quantified as the area under the concentration–time curve at steady state (AUC24) at the average daily dose received, up to the MFS event. Exposure levels were evaluated as quartiles or continuous variables. Univariate and multivariate Cox regression models evaluated the relationship between APA/NAPA exposure and MFS and were adjusted by pre-specified stratification factors (prostate-specific antigen doubling time, bone-sparing agent use, locoregional disease status) and other potential prognostic factors (age, ECOG PS).
Results
1206 pts were included in the analysis. AEs led to dose reduction/interruption in 33% vs 19% of APA and PBO pts, respectively, with average daily dose of 225 mg (APA) vs 229 mg (PBO) in pts with dose reduction/interruption. Mean (coefficient of variation [CV]%) PK exposure levels measured as AUC24 for APA and NAPA, respectively, were 117 (24 CV%) μg·h/mL and 155 (17 CV%) μg·h/mL for APA-treated pts without dose reductions/interruptions, and 112 (24 CV%) μg·h/mL and 148 (18 CV%) μg·h/mL for those with dose reductions/interruptions. MFS benefit was similar across the range of APA/NAPA exposures. In univariate and multivariate Cox regression models, no significant differences in the exposure-MFS relationship were observed for APA and NAPA.
Conclusions
240 mg/d APA provided efficacious drug exposure for the majority of pts, including those who required dose reductions/interruptions due to AEs. The MFS benefit was similar across the range of APA exposure. Dose reductions/interruptions due to AEs did not reduce the efficacy of APA.
Clinical trial identification
NCT01946204.
Legal entity responsible for the study
Janssen Research & Development.
Funding
Janssen Research & Development.
Editorial Acknowledgement
Writing assistance was provided by Brian Haas, PhD, of PAREXEL, and was funded by Janssen Global Services, LLC.
Disclosure
M.R. Smith: Grants: Janssen; Personal fees: Janssen, Astellas, Bayer. C. Perez-Ruixo, O. Ackaert, D. Ouellet, C. Chien, M.K. Yu, J-J. Perez-Ruixo: Employee: Janssen Research & Development; Stock owner: Johnson & Johnson. H. Uemura: Personal fees: Janssen, Astellas, Takeda, Sanofi, Bayer, Astra-Zeneca. D. Olmos: Grants: Janssen, Astellas, Bayer, Sanofi, Genentech, Astra-Zeneca, Bayer, outside the submitted work. P.N. Mainwaring: Personal fees: XING Technologies P/L, Ipsen, Janssen, Merck, Novartis, Pfizer, Roche; Grants: Merck; Pending patent: XING Technologies P/L: All other authors have declared no conflicts of interest.
Resources from the same session
2069 - The concordance with antiemetic guideline for pediatric, adolescent and young adult patients with cancer using a large-scale administrative database.
Presenter: Seiko Bun
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2740 - Effectiveness of surgical glove compression therapy as a prophylactic method against nab-Paclitaxel induced peripheral neuropathy
Presenter: Shigeru Tsuyuki
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2229 - Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)
Presenter: Hubert Piessevaux
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4155 - Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV)
Presenter: Antony Mersiades
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2473 - Pregnancies after breast cancer, is there a real need for fertility preservation ? Results from the ARTEMIS cohort of 60 young patients
Presenter: Jerome Martin-Babau
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3450 - Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: a reality or a myth?
Presenter: Aurore Vozy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2917 - Indicators of non-uptake of breast cancer screening: results from the EDIFICE 6 survey
Presenter: Jean-Francois Morere
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2920 - Benefits of physical activity and sport integrated into the care pathway of oncology patient
Presenter: Laurence Vanlemmens
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5334 - Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study
Presenter: Quan Tran
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
6108 - Quality of life, late effects, and related clinical factors among Korean colorectal cancer survivors
Presenter: Ji Soo Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract